FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “PSYC Primed for Launch During Covid-19.”
Global Trac Solutions, Inc. (OTC: PSYC) is pleased to announce they have engaged with a variety of key industry experts in an effort to plan and prepare for the Company’s intended initial launch set for May 2020. Such efforts have included identifying and establishing strategic partnerships with various individuals and companies whom PSYC will look to collaborate with over the next several weeks and months. The Company will be working on collaborations in the areas of media, website and brand strategy as it positions itself for what it anticipates to be a very effective launch into the emerging business sector of psychedelic medicine.
Global Trac Solutions is a diversified holding company dedicated to identifying new and emerging industries. By utilizing our years of business development expertise our diverse team of innovators continuously leverages our experience to effectively execute go-to-market strategies in order to position ourselves for rapid growth through the creation of an evolving business foundation to enhance profitability potential.
Over the course of the past decade, several universities and research institutes have published breakthrough findings from studies conducted on the usefulness and applications of psilocybin. The substance was studied for use in the treatment of anxiety disorders such as OCD, addiction to alcohol, tobacco and opioids, treatment-resistant depression, PTSD as well as chronic migraines. Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms. Just last year, the Johns Hopkins School of Medicine opened the Center for Psychedelic and Consciousness Research in Baltimore. Headed by renowned researcher Roland R. Griffiths, Ph.D., the Center aims to research the use of psychedelics to study the mind and identify therapies for diseases such as addiction, PTSD and Alzheimer’s. According to the university, a group of private donors has given USD 17 Million to start the Center, making it what’s believed to be the first such research center in the U.S., and the largest research center of its kind in the world.
Psychedelic products have slowly gain popularity in recent times, similar to cannabis in years past, and finally breaking free of their stigmas. Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS), explained according to an article by Forbes that “the new psychedelic industry will need to focus on public benefit as well as profit in order to avoid a cultural backlash against these historically misunderstood substances.” And even though the psychedelic drugs market is still only in infancy stage, a few announcements have already been made regarding the use of such products. For example, in September 2019, Jazz Pharmaceuticals, Inc. had published optimistic data sets from JZP-258’s Phase 3 study for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.
For more information, please visit: Global Trac Solutions, Inc.
For more corporate news on Global Trac Solutions, Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.